Tegaderm CHG I.V. Securement Dressing is only dressing fully
compliant with updated CDC recommendation and INS Infusion Therapy
Standards of Practice
ST. PAUL, Minn.--(BUSINESS WIRE)--
The Centers for Disease Control (CDC) recently updated its
recommendation on use of chlorhexidine-impregnated dressings in its
globally-recognized Guidelines for the Prevention of Intravascular
Catheter-Related Infections (2011). The new recommendation calls for
use of chlorhexidine-impregnated dressings with an FDA-cleared label
that specifies a clinical indication for reducing catheter-related
bloodstream infection (CRBSI) or catheter-associated bloodstream
infection (CABSI) to protect the insertion site of short-term,
non-tunneled central venous catheters for patients aged 18 years and
older.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171117005655/en/
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing is only dressing fully compliant with updated CDC recommendation and INS Infusion Therapy Standards of Practice (Photo: 3M)
3M Tegaderm CHG I.V. Securement Dressing remains the only transparent
dressing indicated and proven to reduce CRBSI, aligning with
evidence-based guidelines and practice standards. This includes the 2016 Infusion
Therapy Standards of Practice recommendation for the use of
transparent dressings that permit continuous visual inspection of the
catheter site.1
“The CDC’s evidence-based recommendations elevate current best practices
in reducing life-threatening and costly bloodstream infections. The
revisions highlight the strong clinical data that supports use of
Tegaderm CHG I.V. Securement Dressing worldwide,” said Pat Parks, MD,
PhD, medical director for 3M Critical and Chronic Care Solutions
Division. “At 3M, our goal is zero bloodstream infections. We’ll keep
innovating and educating to make that future possible.”
Tegaderm CHG I.V. Securement Dressing meets the CDC’s highest
evidence-based recommendation category, IA, meaning it is a strong
recommendation supported by high-to-moderate quality evidence suggesting
net clinical benefits or harms. This evidence includes a randomized
controlled trial of 1,879 subjects that found Tegaderm CHG I.V.
Securement Dressing reduced CRBSI by 60 percent in patients with central
and arterial lines (p=0.020).2 The Dressing provides an
integrated solution that offers infection reduction, site visibility,
consistent application and catheter securement in one easy-to-use
product to provide a more convenient and reliable solution for I.V. care
and maintenance.
For more information about the clinical evidence supporting Tegaderm CHG
I.V. Securement Dressing and how the Dressing meets other industry
standards and guidelines, please visit 3M.com/TegadermCHG.
3M and Tegaderm are trademarks of 3M Company.
About 3M
At 3M, we apply science in collaborative ways to
improve lives daily. With $30 billion in sales, our 90,000 employees
connect with customers all around the world. Learn more about 3M’s
creative solutions to the world’s problems at www.3M.com or
on Twitter @3M or @3MNews.
1 Infusion Nurses Society (INS). Infusion Therapy
Standards of Practice. INS; 2016.
2 Timsit JF et al. Randomized
controlled trial of chlorhexidine dressing and highly adhesive dressing
for preventing catheter-related infections in critically ill adults.
Am J Crit Care Med. 2012;186(12): 1272-1278 http://www.atsjournals.org/doi/pdf/10.1164/rccm.201206-1038OC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171117005655/en/
Source: 3M